{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:34:08Z","timestamp":1781192048124,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03893-0","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:25:12Z","timestamp":1750231512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased GPR35 expression is correlated with poor prognosis in prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Tianyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abudukeyoumu","family":"Maimaitiyiming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"3","key":"3893_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3893_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3893_CR3","first-page":"502","volume":"34","author":"W Chen","year":"2015","unstructured":"Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortalities of major cancers in china, 2011. Chin J Cancer. 2015;34(11):502\u20137.","journal-title":"Chin J Cancer"},{"issue":"10","key":"3893_CR4","doi-asserted-by":"publisher","first-page":"e2440381","DOI":"10.1001\/jamanetworkopen.2024.40381","volume":"7","author":"M Li","year":"2024","unstructured":"Li M, Hu M, Jiang L, Pei J, Zhu C. Trends in Cancer incidence and potential associated factors in China. JAMA Netw Open. 2024;7(10):e2440381.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"3893_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","volume":"18","author":"G Devos","year":"2021","unstructured":"Devos G, Devlies W, De Meerleer G, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18(12):739\u201362.","journal-title":"Nat Rev Urol"},{"key":"3893_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate Cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"issue":"2","key":"3893_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate Cancer. Eur Urol. 2015;68(2):325\u201334.","journal-title":"Eur Urol"},{"issue":"1","key":"3893_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2013.08.081","volume":"83","author":"SD Foss\u00e5","year":"2014","unstructured":"Foss\u00e5 SD, Nilssen Y, Kv\u00e5le R, Hernes E, Axcrona K, M\u00f8ller B. Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience. Urology. 2014;83(1):146\u201352.","journal-title":"Urology"},{"issue":"6b","key":"3893_CR9","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.1111\/bju.12554","volume":"114","author":"SY Wang","year":"2014","unstructured":"Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014;114(6b):E18\u201324.","journal-title":"BJU Int"},{"issue":"4","key":"3893_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbamem.2006.09.029","volume":"1768","author":"PA Insel","year":"2007","unstructured":"Insel PA, Tang CM, Hahntow I, Michel MC. Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta. 2007;1768(4):994\u20131005.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"3893_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/bph.14082","volume":"175","author":"SJ Park","year":"2018","unstructured":"Park SJ, Lee SJ, Nam SY, Im DS. GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17? Br J Pharmacol. 2018;175(1):154\u201361.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3893_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1021\/acsptsci.0c00079","volume":"3","author":"T Quon","year":"2020","unstructured":"Quon T, Lin LC, Ganguly A, Tobin AB, Milligan G. Therapeutic opportunities and challenges in targeting the orphan G Protein-Coupled receptor GPR35. ACS Pharmacol Transl Sci. 2020;3(5):801\u201312.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"3893_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s43440-022-00371-2","volume":"74","author":"T Mackiewicz","year":"2022","unstructured":"Mackiewicz T, Jacenik D, Talar M, Fichna J. The GPR35 expression pattern is associated with overall survival in male patients with colorectal cancer. Pharmacol Rep. 2022;74(4):709\u201317.","journal-title":"Pharmacol Rep"},{"issue":"7","key":"3893_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.17219\/acem\/157291","volume":"32","author":"T Mackiewicz","year":"2023","unstructured":"Mackiewicz T, W\u0142odarczyk J, Zieli\u0144ska M, et al. Increased GPR35 expression in human colorectal and pancreatic cancer samples: A preliminary clinical validation of a new biomarker. Adv Clin Exp Med. 2023;32(7):783\u20139.","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"3893_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.bbrc.2017.09.113","volume":"493","author":"YJ Guo","year":"2017","unstructured":"Guo YJ, Zhou YJ, Yang XL, Shao ZM, Ou ZL. The role and clinical significance of the CXCL17-CXCR8 (GPR35) axis in breast cancer. Biochem Biophys Res Commun. 2017;493(3):1159\u201367.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"3893_CR16","first-page":"2426","volume":"13","author":"J Yue","year":"2023","unstructured":"Yue J, Guo H, Xu P, Ma J, Wu Y. Activation of the GPR35 on ILC2 drives immunosuppression to promote lung cancer progression. Am J Cancer Res. 2023;13(6):2426\u201338.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"3893_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4103\/aja.aja_117_18","volume":"21","author":"M Zhang","year":"2019","unstructured":"Zhang M, Guan J, Huo YL, Song YS, Chen LZ. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy. Asian J Androl. 2019;21(4):387\u201392.","journal-title":"Asian J Androl"},{"issue":"2","key":"3893_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10552-007-9083-8","volume":"19","author":"R Etzioni","year":"2008","unstructured":"Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175\u201381.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"3893_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrurol.2016.251","volume":"14","author":"K Fleshner","year":"2017","unstructured":"Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14(1):26\u201337.","journal-title":"Nat Rev Urol"},{"issue":"7","key":"3893_CR20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/jamainternmed.2017.0340","volume":"177","author":"SA Fedewa","year":"2017","unstructured":"Fedewa SA, Ward EM, Brawley O, Jemal A. Recent patterns of prostate-Specific antigen testing for prostate Cancer screening in the united States. JAMA Intern Med. 2017;177(7):1040\u20132.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"3893_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1515\/cclm-2019-0693","volume":"58","author":"MJ Duffy","year":"2020","unstructured":"Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med. 2020;58(3):326\u201339.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"3893_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/andr.12322","volume":"5","author":"P Shen","year":"2017","unstructured":"Shen P, Zhao J, Sun G, et al. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng\/ml. Andrology. 2017;5(3):548\u201355.","journal-title":"Andrology"},{"issue":"8","key":"3893_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms20081813","volume":"20","author":"I Kohaar","year":"2019","unstructured":"Kohaar I, Petrovics G, Srivastava S. A rich array of prostate Cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20(8):1813.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3893_CR24","doi-asserted-by":"publisher","first-page":"101042831985888","DOI":"10.1177\/1010428319858885","volume":"41","author":"H Ali","year":"2019","unstructured":"Ali H, AbdelMageed M, Olsson L, et al. Utility of G protein-coupled receptor 35 expression for predicting outcome in colon cancer. Tumour Biol. 2019;41(6):1010428319858885.","journal-title":"Tumour Biol"},{"issue":"3","key":"3893_CR25","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3892\/ol.2020.11819","volume":"20","author":"H Yao","year":"2020","unstructured":"Yao H, Lv Y, Bai X, Yu Z, Liu X. Prognostic value of CXCL17 and CXCR8 expression in patients with colon cancer. Oncol Lett. 2020;20(3):2711\u201320.","journal-title":"Oncol Lett"},{"key":"3893_CR26","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.2147\/OTT.S175606","volume":"11","author":"W Wang","year":"2018","unstructured":"Wang W, Han T, Tong W, Zhao J, Qiu X. Overexpression of GPR35 confers drug resistance in NSCLC cells by \u03b2-arrestin\/Akt signaling. Onco Targets Ther. 2018;11:6249\u201357.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3893_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/ijms24010615","volume":"24","author":"Y Li","year":"2022","unstructured":"Li Y, Liu A, Liu S, Yan L, Yuan Y, Xu Q. Involvement of CXCL17 and GPR35 in gastric Cancer initiation and progression. Int J Mol Sci. 2022;24(1):615.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3893_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41420-022-01238-4","volume":"8","author":"C Shu","year":"2022","unstructured":"Shu C, Wang C, Chen S, et al. ERR-activated GPR35 promotes immune infiltration level of macrophages in gastric cancer tissues. Cell Death Discov. 2022;8(1):444.","journal-title":"Cell Death Discov"},{"issue":"5","key":"3893_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/CAD.0000000000001280","volume":"33","author":"J Hao","year":"2022","unstructured":"Hao J, Gao X, Wang YP, et al. Expression and clinical significance of CXCL17 and GPR35 in endometrial carcinoma. Anticancer Drugs. 2022;33(5):467\u201377.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"3893_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tips.2023.03.001","volume":"44","author":"G Milligan","year":"2023","unstructured":"Milligan G. GPR35: from enigma to therapeutic target. Trends Pharmacol Sci. 2023;44(5):263\u201373.","journal-title":"Trends Pharmacol Sci"},{"issue":"562","key":"3893_CR31","doi-asserted-by":"publisher","first-page":"eaau9048","DOI":"10.1126\/scisignal.aau9048","volume":"12","author":"G Schneditz","year":"2019","unstructured":"Schneditz G, Elias JE, Pagano E, et al. GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Sci Signal. 2019;12(562):eaau9048.","journal-title":"Sci Signal"},{"issue":"3","key":"3893_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/gutjnl-2020-323363","volume":"71","author":"E Pagano","year":"2022","unstructured":"Pagano E, Elias JE, Schneditz G, et al. Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment. Gut. 2022;71(3):509\u201320.","journal-title":"Gut"},{"issue":"3","key":"3893_CR33","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.apsb.2020.07.017","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Li D, Zhang Y, et al. Functional metabolomics reveal the role of AHR\/GPR35 mediated kynurenic acid gradient sensing in chemotherapy-induced intestinal damage. Acta Pharm Sin B. 2021;11(3):763\u201380.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3893_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12894-023-01259-w","volume":"23","author":"T Hwang","year":"2023","unstructured":"Hwang T, Oh H, Lee JA, Kim EJ. Prostate cancer risk prediction based on clinical factors and prostate-specific antigen. BMC Urol. 2023;23(1):100.","journal-title":"BMC Urol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03893-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03893-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:25:13Z","timestamp":1750231513000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03893-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03893-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the General Hospital of Xinjiang Military Region of the Chinese People\u2019s Liberation Army and conducted in accordance with the 1996 Declaration of Helsinki. The Ethics Committee of the General Hospital of Xinjiang Military Region of the Chinese People\u2019s Liberation Army waived informed consent from participants because this study involved routinely collected medical data that were managed anonymously at all stages, including the data cleaning and statistical analysis stages.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}